FDA 483 - ENDO Pharmaceuticals Solutions, Inc. - October 23, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
ENDO Pharmaceuticals Solutions, Inc. in Cranbury, NJ, received a Form 483 with five observations highlighting significant deficiencies. The inspection revealed issues in preventing microbiological contamination, maintaining aseptic processing areas, and ensuring adequate laboratory controls for product testing. Additionally, the firm failed to thoroughly investigate out-of-specification results for drug product components, which were linked to patient complaints for distributed implant lots.
ID · 0470733a-57bb-4e4b-9ba6-c481522df941